Transition Therapeutics Inc.

(TTH:CA)

By |

Profile

Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease.

Contact Information

Website: www.transitiontherapeutics.com
Email: info@transitiontherapeutics.com
Main Phone: +1 416 260-7770
Address: 101 College Street
Address 2: Suite 220
State: ON
City / Town: Toronto
Country: CA
Postal Code: M5G 1L7

Issuer Information

Exchange: TSX
CEO: Tony F. Cruz
Employees: 18
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease.

Contact Information

Website: www.transitiontherapeutics.com
Email: info@transitiontherapeutics.com
Main Phone: +1 416 260-7770
Address: 101 College Street
Address 2: Suite 220
State: ON
City / Town: Toronto
Country: CA
Postal Code: M5G 1L7

Issuer Information

Exchange: TSX
CEO: Tony F. Cruz
Employees: 18
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 1.93 $ 0. (0.00%)
Last Price 1.93 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close 1.93
Last Trade Volume 0 52 Wk Hi 3.54 52 Wk Low 0.89
Market Cap 74.9 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 38,798,971.00 EPS (TTM) -0.65 PE Ratio N/A Exchange TSX
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 5.5 5.5 5.5 5.5
Low Target Price Estimate 5.5 5.5 5.5 5.5
Mean Target Price Estimate 5.5 5.5 5.5 5.5
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 04/29/14 04/29/14 04/29/14 04/29/14
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 0 0 0 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 0 0 0 3

© 2021 Equities News | Equities.com, Inc.

* All dates and time are being displayed in Eastern Standard Time (EST).